Client Description

GlaxoSmithKline plc is a research-based pharmaceutical company. The Company develops, manufactures, and markets vaccines, prescription, and over-the-counter medicines, as well as health-related consumer products. GlaxoSmithKline provides products for infections, depression, skin conditions, asthma, heart and circulatory disease, and cancer.

GlaxoSmithKline (GSK) gives anxiety, asthma, and other ailments the ax. One of the top five pharmaceutical firms in the world, GSK’s bestsellers include respiratory, neurological, cardiovascular and dermatology drugs, as well as vaccines and antivirals. Its top product is asthma medication Advair (aka Seretide), which combines two of its other asthma products, Flovent and Serevent. Other bestsellers include epilepsy treatment Lamictal, cholesterol medicine Lovaza, and prostate enlargement treatment Avodart. GSK’s consumer products include Tums, dental care products Aquafresh and Sensodyne, and smoking-cessation products NicoDerm and Nicorette. In 2015 GSK bought Novartis’ Vaccines and Consumer Health business, and sold its cancer drugs business to the same company.

GSK operates through three primary segments – Pharmaceuticals, Consumer Healthcare and Vaccines. Pharmaceuticals is the largest by far, pulling in some 60% of revenue.

The Pharmaceuticals business develops and makes medicines that treat a wide variety of acute and chronic diseases.Respiratory drugs is its largest sales category, primarily due to blockbuster Advair, which brings in around £4 billion annually. Other respiratory products include Ventolin, Relvar, and Flixotide. GSK also has a strong presence in the HIV market (through majority-owned ViiV Healthcare), as well as the central nervous system treatment market alongside cardiovascular, urogenital, dermatology (through its Stiefel division), virology, infectious disease, and metabolism.

Consumer Healthcare products fall into the oral health, wellness, nutrition, and skin health categories, with top sellers including Sensodyne, Panadol, and Horlicks. The segment also makes key brands Theraflu, Polident and Abreva. GSK sells these products in more than 150 countries around the world, with around 40% of sales in emerging markets. In 2015, GSK combined its consumer health care operations with those of Novartis to create a global leader in the consumer health market.

The Vaccines business is a global leader, with around 40 pediatric, adolescent, adult, and travel vaccines on the market. Its Infanrix childhood vaccine for diphtheria and tetanus leads the pack, followed by products for the prevention of hepatitis, pneumonia, rotavirus, and influenza, with brands including Cervarix and Pediarix vaccines and antibiotic Augmentin. As part of the Novartis acquisition GSK gained two meningitis vaccines, Menveo and Bexsero.

GSK has more than 80 manufacturing facilities in 36 countries. The group’s major R&D centers are located in the UK, the US, Belgium, and China. It has a presence in more than 115 countries.

The company markets its products directly to hospitals, pharmacies, doctors, and other health care consumers; it also uses wholesale distributors in some markets and serves customers in more than 150 countries overall.

  • Tools: MicroStrategy | Oracle
  • Categories: Analytics, Big Data, Strategy
  • Tags: Healthcare